More on EOLS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+85.2% Growth)
- Ratings (7.7 Score)

Upcoming Events

- Earnings (8/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Evolus (NQ:EOLS)
Delayed: 5.98 -0.01 (0.17%)
Prev. Close $5.99  
Open$6.00 
52 Wk High$ 
52 Wk Low$ 
Day High$6.04 
Day Low$5.85 
P/E N/A  
EPS$ 
Volume696,862 


Jul 22, 2026 08:30 AM Evolus to Report Second Quarter Financial Results on August 5, 2026
Jul 10, 2026 04:05 PM Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 8, 2026 09:04 AM Form 8-K Evolus, Inc. For: Jul 07
Jul 8, 2026 09:02 AM Evolus strikes licensing deal with IBSA to bring Profhilo to US
Jul 8, 2026 09:00 AM Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Jun 15, 2026 06:23 AM Form EFFECT Evolus, Inc.
Jun 12, 2026 04:19 PM Form 8-K Evolus, Inc. For: Jun 11
Jun 5, 2026 04:49 PM Evolus (EOLS) files $250M mixed shelf
Jun 5, 2026 04:46 PM Form S-3 Evolus, Inc.
May 19, 2026 08:30 AM Evolus to Participate in The Jefferies Global Healthcare Conference
View All Articles

Entities mentioned with EOLS

View All Entities